WO2022249146 - Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
National phase entry:
Publication Number
WO/2022/249146
Publication Date
01.12.2022
International Application No.
PCT/IB2022/055019
International Filing Date
27.05.2022
Title **
[English]
Fc VARIANT WITH ENHANCED AFFINITY TO Fc RECEPTORS AND IMPROVED THERMAL STABILITY
[French]
VARIANT FC À AFFINITÉ AMÉLIORÉE VIS-À-VIS DE RÉCEPTEURS FC ET STABILITÉ THERMIQUE AMÉLIORÉE
Applicants **
SANOFI
46 avenue de la Grande Armée
75017 Paris, FR
Inventors
BENINGA, Jochen
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main, DE
CAMERON, Béatrice
c/o Sanofi
Patent Department
46 avenue de la Grande Armée
75017 Paris, FR
FOCKEN, Ingo
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main, DE
KATHURIA, Sagar
c/o Sanofi
Patent Department
450 Water Street
Cambridge, Massachusetts 02141, US
LANGE, Christian
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main, DE
MASIERO, Alessandro
c/o Sanofi
Patent Department
46 avenue de la Grande Armée
75017 Paris, FR
PARK, Sunghae
c/o Sanofi
Patent Department
450 Water Street
Cambridge, Massachusetts 02141, US
TILLMANN, Bodo
c/o Sanofi-Aventis Deutschland GmbH
65926 Frankfurt am Main, DE
Priority Data
63/193,665
27.05.2021
US
21315127.7
15.07.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 5289 | |
| EPO | Filing, Examination | 97000 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 29360 |
Total: 132845 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides Fc domain variants, including effector-competent Fc domain variants. The present disclosure also provides nucleic acids encoding Fc domain variants and host cells for making Fc domain variants. Methods for increasing the yield of Fc domain variants, and methods of using Fc domain variants to treat disease, are also provided.[French]
La présente invention concerne des variants de domaine Fc, comprenant des variants de domaine Fc effecteur compétent. La présente invention concerne également des acides nucléiques codant pour des variants de domaine Fc et des cellules hôtes pour la fabrication de variants de domaine Fc. L'Invention concerne également des procédés pour augmenter le rendement de variants de domaine Fc et des procédés d'utilisation de variants de domaine Fc pour traiter une maladie.